<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482287</url>
  </required_header>
  <id_info>
    <org_study_id>MTR-105-US-102</org_study_id>
    <nct_id>NCT00482287</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients</brief_title>
  <official_title>A Phase II, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study to Assess the Pharmacokinetics and Pharmacodynamics of MTR105 in Cardiac Surgery Induced Hypotension Patients During Weaning Off Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meditor Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meditor Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetic and the pharmacodynamic
      effects of escalating doses of MTR105 while weaning from bypass in a hypotensive population
      of cardiac surgery patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, randomized, four-arm, dose-escalating, double blind, placebo
      controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of four dose
      levels of MTR105 in patients undergoing cardiac surgery utilizing cardiopulmonary bypass
      presenting hypotension upon weaning off bypass.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Site did not recruit any patients
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic parameters</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypotension</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose level 0.3 mg/kg with 6 active and 2 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose level 0.6 mg/kg 6 patients active and 2 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose level 1.2 mg/kg 6 active and 2 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose level 2.4 mg/kg 6 active and 2 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTR105</intervention_name>
    <description>Intravenous administration, dose escalating (4 arms), single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women age 18 years or older

          -  Referred for cardiac surgery requiring the use of CPB.

          -  Elective or urgent surgeries (non emergency operations).

          -  LVEF â‰¥40 based on cardiac catheterization results

          -  Normal renal function at study entry

          -  Normal hepatic function (within normal laboratory ranges) at study entry

          -  Normal coagulation status at study entry as judged by PT, PTT, fibrinogen and platelet
             count.

          -  Willingness to participate in the study and adhere to the study design.

          -  Willingness to sign an informed consent form.

        Exclusion Criteria:

          -  Emergency operation

          -  Pulmonary hypertension (PA systolic pressure &gt;60 mmHg)

          -  Ejection fraction less than 35% during weaning from bypass or cardiac index of less
             than 1.8

          -  Neurological events such as prior CVA, TIA or symptomatic carotid stenosis within 1
             year of presenting for surgery

          -  Body weight &lt;40 Kg

          -  Pregnancy

          -  Malignancy within 1 year of presenting for surgery

          -  Systemic infection as evidenced by elevated WBC or fever &gt;38.5 C

          -  Usage of vasoactive medications within 24 hours except short term use of a
             vasoconstrictor during induction.

          -  Participation in any other investigational drug or device study within 30 days of
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny Sappington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <name_title>Adrian Harel</name_title>
    <organization>Meditor Pharmaceuticals Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

